Capital World Investors filed Amendment No. 7 to its Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 10,814,817 shares of ThredUp Inc. common stock as of September 30, 2026.
Capital World Investors filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 4,849,198 shares of Essent Group Ltd. common stock as of September 30, 2026.
Capital World Investors filed Amendment No. 6 to Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 8,062,764 shares of Wayfair Inc. common stock as of September 30, 2026.
Capital World Investors filed Amendment No. 2 to Schedule 13G with the SEC on November 13, 2026, disclosing a beneficial ownership position of 14,543,459 shares of common stock in Ingersoll-Rand, Inc. (NYSE:IR), representing 3.7% of shares believed to be outstanding as of September 30, …
Capital World Investors filed an amended beneficial ownership statement with the SEC on November 13, 2026, disclosing a 7.6% stake in Corteva, Inc. (NYSE:CTVA) as of September 30, 2026.
Capital World Investors filed an amended Schedule 13G with the SEC on November 11, 2026, disclosing beneficial ownership of 5,379,613 shares of Zillow Group, Inc. common stock as of September 30, 2026.
Capital World Investors filed an amended beneficial ownership statement with the SEC on November 13, 2026, disclosing a 3.7% stake in Rocket Companies, Inc. as of September 30, 2026.
Capital World Investors filed a Schedule 13G with the SEC on November 11, 2026, disclosing beneficial ownership of 938,588 shares of CSW Industrials, Inc. common stock, representing 5.8% of the class, as of September 30, 2026.
Capital World Investors filed Amendment No. 4 to Schedule 13G with the SEC on November 11, 2026, disclosing beneficial ownership of 21,708,810 shares of Performance Food Group Co. common stock as of September 30, 2026.
Capital World Investors filed a Schedule 13G with the SEC on November 11, 2026, disclosing beneficial ownership of 8,255,584 shares of Definium Therapeutics, Inc. common stock, representing 6.1% of the class, as of a triggering event dated September 30, 2026.